2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 37

Discovery of DWP213388, a Potent ITK and BTK Dual Target Inhibitor with Excellent Efficacy, As a Treatment for Autoimmune Diseases

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 447

Discriminating between Central & Peripheral Pain Sensitization Using a Slowly Repeated Evoked Pain Protocol

Pain Mechanisms – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 614

Disease Activity One Year after Addition of Bucillamine or Sulfasaladine to Methotrexate in Japanese Patients with Rheumatoid Arthritis : Propensity Score Analysis

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 652

Disease Interception in Psoriasis Patients with Subclinical Joint Inflammation By Interleukin 17 Inhibition with Secukinumab – Data from a Prospective Open Label Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 543

Disease Severity Among Bio-Naive RA Patients on Csdmards

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 265

Disparities in Utilization and Direct Costs of Hospitalizations and Emergency Room Visits in SLE: The Georgia Lupus Registry

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 221

Distal Interphalangeal Joint Involvement and Its Association with Disease Activity in Rheumatoid Arthritis (RA): Analysis Based on a Nationwide RA Database in Japan

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 138

Distinct Roles of Tfh2, SLAMF7+ Tfh1 Cells and Th1 Cells in the Pathogenesis of IgG4-RD

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 207

Divergent Patterns of Cardiovascular Risk in Biomarkers of Lipids and Subclinical Myocardial Injury during Increased Inflammation in Rheumatoid Arthritis

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 622

DMARD Withdrawal in RA Patients Achieving Therapeutic Response with Certolizumab Pegol Combined with Dmards: Results from a Canadian Randomized Study

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 829

DNA Damage and Repair in Patients with Cryoglobulinemic Vasculitis Treated with Direct Anti-HCV Drugs

Vasculitis Poster I: Non-ANCA-Associated and Related Disorders

9:00AM-11:00AM: Abstract Number: 74

DNA Methylation of the Dual Specificity Protein Phosphatase 22 (DUSP22) Gene Promoter in Plasma of Patients with Seropositive and Seronegative RA

Rheumatoid Arthritis – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 646

Do Ethnicity, Degree of Family Relationship, and the Spondyloarthritis Subtype in Affected Relatives Influence the Association between a Positive Family History for Spondyloarthritis and HLA-B27 Carriership? Results from the Worldwide ASAS Cohort

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 313

Do Musculoskeletal Ultrasound and Magnetic Resonance Imaging Identify Synovitis and Tenosynovitis at the Same Joints and Tendons? – a Comparative Study in Patients Presenting with Early Arthritis and Clinically Suspect Arthralgia

Imaging of Rheumatic Diseases Poster I: MRI

9:00AM-11:00AM: Abstract Number: 339

Documenting Bone Health for Veterans with Rheumatoid Arthritis in an Outpatient Academic Clinic

Measures and Measurement of Healthcare Quality Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].